Free Trial
Thank you for registering! Take a moment to confirm your subscription to MarketBeat Daily Ratings so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.
Send Confirmation Email

Arbutus Biopharma (ABUS) News Today

→ 4 Cryptos BETTER than Bitcoin (From True Market Insiders) (Ad)
Free ABUS Stock Alerts
$2.98
+0.09 (+3.11%)
(As of 05/17/2024 08:53 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media
May 17 at 8:31 PM | morningstar.com
Arbutus Biopharma Corp ABUS
May 17 at 3:30 PM | bizjournals.com
Mike Sofia, who discovered cure for hepatitis C, set to retire from Arbutus Biopharma
May 17 at 3:30 PM | finance.yahoo.com
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program
May 17 at 3:30 PM | finance.yahoo.com
Update: Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program
May 17 at 9:00 AM | businesswire.com
Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value
May 15, 2024 | americanbankingnews.com
Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Up 12.4% in April
May 11, 2024 | americanbankingnews.com
Arbutus Biopharma (NASDAQ:ABUS) Stock Passes Above 200-Day Moving Average of $2.44
May 10, 2024 | msn.com
Arbutus Biopharma to Engage Investors at Upcoming New York Conferences
May 7, 2024 | globenewswire.com
Arbutus to Participate in Two Upcoming Investor Conferences
May 3, 2024 | markets.businessinsider.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Arbutus Biopharma (ABUS), Neurocrine (NBIX) and Bausch Health Companies (BHC)
May 3, 2024 | finance.yahoo.com
Arbutus Biopharma Corp (ABUS) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
May 3, 2024 | finance.yahoo.com
Arbutus Biopharma First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
May 3, 2024 | finance.yahoo.com
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript
May 3, 2024 | marketbeat.com
Arbutus Biopharma's (ABUS) Buy Rating Reaffirmed at Chardan Capital
Chardan Capital reissued a "buy" rating and issued a $4.00 price target on shares of Arbutus Biopharma in a research note on Friday.
May 3, 2024 | msn.com
Arbutus Biopharma Makes Headway in Hepatitis B Treatment and Defends Intellectual Property Amidst Q1 2024 Financial Release
May 2, 2024 | finance.yahoo.com
Arbutus Biopharma Corp Reports Q1 2024 Earnings: A Detailed Financial Review
May 2, 2024 | investorplace.com
ABUS Stock Earnings: Arbutus Biopharma Beats EPS, Misses Revenue for Q1 2024
May 2, 2024 | washingtonpost.com
Arbutus: Q1 Earnings Snapshot
May 2, 2024 | globenewswire.com
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 2, 2024 | globenewswire.com
Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
May 1, 2024 | markets.businessinsider.com
Arbutus Biopharma earnings: here's what to expect
May 1, 2024 | msn.com
Arbutus Biopharma Q1 2024 Earnings Preview
April 30, 2024 | money.usnews.com
Arbutus Biopharma Corp
April 21, 2024 | msn.com
Arbutus Biopharma Sets Date for Q1 2024 Financial Results
April 18, 2024 | globenewswire.com
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
April 10, 2024 | seekingalpha.com
Arbutus Biopharma: The Markman Win Is A Good Milestone But Uncertainty Remains
April 4, 2024 | msn.com
Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judge
April 4, 2024 | marketbeat.com
Arbutus Biopharma (NASDAQ:ABUS) Sees Unusually-High Trading Volume
Arbutus Biopharma (NASDAQ:ABUS) Sees Large Volume Increase
April 4, 2024 | markets.businessinsider.com
Arbutus Biopharma Reports Claim Construction Ruling In Patent Infringement Lawsuit Against Moderna
April 4, 2024 | marketbeat.com
Arbutus Biopharma (NASDAQ:ABUS) Earns "Market Outperform" Rating from JMP Securities
JMP Securities reiterated a "market outperform" rating and issued a $4.00 price objective on shares of Arbutus Biopharma in a research note on Thursday.
April 4, 2024 | globenewswire.com
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
April 3, 2024 | marketbeat.com
Arbutus Biopharma (NASDAQ:ABUS) Hits New 52-Week High at $3.25
Arbutus Biopharma (NASDAQ:ABUS) Reaches New 52-Week High at $3.25
April 3, 2024 | seekingalpha.com
Arbutus Biopharma jumps after claim construction order in patent fight with Moderna
April 3, 2024 | marketbeat.com
Trading was temporarily halted for "ABUS" at 12:04 PM with a stated reason of "LULD pause." Trading set to resume at 12:04 PM.
April 1, 2024 | finance.yahoo.com
Is Arbutus Biopharma (NASDAQ:ABUS) In A Good Position To Deliver On Growth Plans?
March 19, 2024 | finance.yahoo.com
ABUS Jan 2025 7.000 call
March 14, 2024 | marketbeat.com
Hudson Bay Capital Management LP Purchases 1,302,978 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS)
Hudson Bay Capital Management LP lifted its position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) by 45.8% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,149,904 shares of the bioph
March 12, 2024 | msn.com
Arbutus Biopharma to Participate in Prominent Investor Conferences
March 8, 2024 | globenewswire.com
Arbutus to Participate in Two Upcoming Investor Conferences
March 6, 2024 | marketbeat.com
Arbutus Biopharma Target of Unusually Large Options Trading (NASDAQ:ABUS)
Arbutus Biopharma Co. (NASDAQ:ABUS - Get Free Report) saw some unusual options trading on Wednesday. Stock traders acquired 31,568 call options on the stock. This represents an increase of 2,744% compared to the typical daily volume of 1,110 call options.
March 6, 2024 | marketbeat.com
FY2024 EPS Estimates for Arbutus Biopharma Co. Raised by Chardan Capital (NASDAQ:ABUS)
Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) - Equities research analysts at Chardan Capital upped their FY2024 EPS estimates for Arbutus Biopharma in a research note issued on Sunday, March 3rd. Chardan Capital analyst K. Nakae now anticipates that the biopharmaceutical company will earn ($
March 3, 2024 | finance.yahoo.com
Arbutus Biopharma Corporation (NASDAQ:ABUS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
March 2, 2024 | finance.yahoo.com
Analysts Just Made A Major Revision To Their Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenue Forecasts
March 1, 2024 | marketbeat.com
Arbutus Biopharma (NASDAQ:ABUS) Releases Quarterly Earnings Results, Meets Estimates
Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) announced its earnings results on Thursday. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, meeting the consensus estimate of ($0.12). The company had revenue of $2.15 million during the quarter, compared to the consensus estimate of $4.74 million. Arbutus Biopharma had a negative net margin of 339.32% and a negative return on equity of 56.45%. During the same period last year, the firm earned ($0.14) earnings per share.
March 1, 2024 | marketbeat.com
Arbutus Biopharma (NASDAQ:ABUS) Given New $5.00 Price Target at HC Wainwright
HC Wainwright reduced their price objective on Arbutus Biopharma from $6.00 to $5.00 and set a "buy" rating on the stock in a research note on Friday.
March 1, 2024 | finance.yahoo.com
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2023 Earnings Call Transcript
March 1, 2024 | marketbeat.com
Arbutus Biopharma (NASDAQ:ABUS) Receives "Buy" Rating from Chardan Capital
Chardan Capital reiterated a "buy" rating and issued a $4.00 price objective on shares of Arbutus Biopharma in a report on Friday.
March 1, 2024 | markets.businessinsider.com
Buy Rating Affirmed for Arbutus Biopharma on Strong Clinical Outlook and Litigation Prospects
March 1, 2024 | finance.yahoo.com
Q4 2023 Arbutus Biopharma Corp Earnings Call
February 29, 2024 | finanznachrichten.de
Arbutus Biopharma Corporation: Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
Get Arbutus Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.

Next President (Not Trump. Not Biden.) (Ad)

Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be Trump.

Click here to see why it will be ______ _________.

ABUS Media Mentions By Week

ABUS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ABUS
News Sentiment
▼
0.32

0.42
▲
Average
Medical
News Sentiment

ABUS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ABUS Articles
This Week
▼
6

2
▲
ABUS Articles
Average Week

Get Arbutus Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:ABUS) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners
Shocking: One AI startup's revenue could surge 4,735%
Manward Press
The Overlooked Retirement Asset You Probably Don’t Own
Crypto 101 Media
Next President (Not Trump. Not Biden.)
The Freeport Society
Urgent Nvidia Warning
Altimetry
Elon’s New Device is About to Shock the World
InvestorPlace
"The Biggest Drug Ever" Is Coming
Behind the Markets
CEO of Biggest AI Chipmaker Just Dropped a Bombshell…
Banyan Hill Publishing
Exposed: 10 CENT Crypto to Explode May 20th?
True Market Insiders